Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotrovimab pediatric PK/PD and safety in high-risk mild to moderate COVID-19
2021-003717-18Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sotrovimab in coronavirus disease 2019 (COVID-19), sponsored by GSK. Primary endpoint: Body weight-adjusted serum clearance of sotrovimab. Started Nov 2021; status: completed.
02
Drugs
sotrovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-003717-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003717-18.